RE:RE:RE:RE:RE:RE:RE:RE:Isolated data on the optimized group Not to be confused with my favorite actor R2D2, R3SS wrote:
"Ok, no doubt Slayer really knows this stuff. Yet as a betting $$ layman, I'm guessing if everything goes well with the second treatment, it should overwhelm the cancer cells, no matter what. Right?"
Healthy 450 day CR data would certainly suggest that....& even if intracellular ROS levels don't reach sledgehammer levels, we have our immune response (immunogenic cell death) hitting cleanup.
Imo, I don't see how this form of ACT doesn't get approved at some point. There's just too much reasearch/data supporting it's utility. However, I also believe there's a good chance over the next decade that this form of ACT will evolve significantly for the better (I.e. used in combo, used as an adjuvant, utilizing expanded forms of PS activation, changes made to treatment timing &/or frequency, etc.). And we can all then look back & give a well-deserved nod to TLT. All imo.